Key facts
- This page summarizes Michael Howell's Form 4 filing for Zura Bio Ltd (ZURA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 24 Apr 2024, 18:54.
Michael Howell - 22 Apr 2024 Form 4 Insider Report for Zura Bio Ltd (ZURA)
- Reporting relationship
- Officer
- Issuer ticker
- ZURA
- Reported as of
- 22 Apr 2024
- Net transaction value
- +$24,999
- SEC form
- 4
- Accepted by SEC
- 24 Apr 2024, 18:54:25 UTC
- Prior SEC filing
- 22 May 2023
- Next SEC filing
- 08 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Howell
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Howell filed Form 4 for Zura Bio Ltd (ZURA) on 24 Apr 2024.
Change
- Previous filing in this sequence was filed on 22 May 2023.
- Current net transaction value: +$24,999.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
This filing has been restated.
Open the amended filing.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZURA
transaction
Class A ordinary shares
Purchase
- Transaction value
- $24,999
- Shares
- +7,987
- Change %
- Price
- $3.13
- Shares after
- 7,987
- Date
- 22 Apr 2024
- Ownership
- By corporation
- Footnotes
- F1, F2
ZURA
holding
Class A ordinary shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 114,395
- Date
- 22 Apr 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares were acquired in a private placement transaction pursuant to the terms of that certain Securities Purchase Agreement, dated as of April 18, 2024, between the Issuer and Mountaineer Biosciences, Inc. ("Mountaineer") at a purchase price of $3.13 per share.
Footnote F2
These shares are beneficially owned by Mountaineer. The Reporting Person is the Co-Founder of Mountaineer and, as such, has the power to vote and dispose of the ordinary shares held by Mountaineer. The Reporting Person disclaims beneficial ownership in these securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.